Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Drug product assays

Case Studies I). Transfer of a Drug Product Assay Method for an Oncology Product... [Pg.32]

Table 2. Statistical parameters for initial hand-over of drug product assay method, based on 4 series of 2 determinations per site (adapted from Agut et al., 2011)... Table 2. Statistical parameters for initial hand-over of drug product assay method, based on 4 series of 2 determinations per site (adapted from Agut et al., 2011)...
Chemical reaction kinetics can be used to evaluate degradation data at accelerated conditions and predict the drug product assay at normal conditions for periods longer than the proposed shelf life. This is applicable to limited cases because the reaction kinetics is often complex for drug products. The following example illustrates the procedure to follow to calculate the API concentration with time for a drug product stored at normal conditions when such data are not yet available. [Pg.628]

Once the specific reaction rate is calculated, the drug product assay can be predicted using Equation (62). The results are shown in Table 30 along with the actual data from Table 28. [Pg.629]

Quantitative tests for the assay of major components (e.g., drug substance and preservatives) in samples of drug substance or drug product (assay, content uniformity, dissolution rate, etc.)... [Pg.456]

As required by regulatory authorities [1-3, 6] and International Conference on Harmonisation (ICH) guidelines [7], analytical method validation is especially important in establishing the assay methods and procedures of quantitative or semi-quantitative measurement of target substances or compounds. Among the specification items for drug products, assay, content uniformity, and dissolution are typical of those which require almost full analytical validation. The purity test, related... [Pg.57]

For drug substances and drug products, applications for enantiomers and racemates should include a stereochemically specific identity test and/or a stereochemically selective assay. The choice of control tests should be based on the method of manufacture and stability characteristics and, in the case of the finished product, its composition. [Pg.329]

Determination of the drug substance is expected to be enantioselective, and this may be achieved by including a chiral assay in the specification or an achiral assay together with appropriate methods of controlling the enantiomeric impurity. For a drug product where racemization does not occur during manufacture or storage, an achiral assay may suffice. If racemization does happen, then a chiral assay should be used or an achiral method combined with a validated procedure to control the presence of the other enantiomer. [Pg.335]

Most chemists tend to think of infrared (IR) spectroscopy as the only form of vibrational analysis for a molecular entity. In this framework, IR is typically used as an identification assay for various intermediates and final bulk drug products, and also as a quantitative technique for solution-phase studies. Full vibrational analysis of a molecule must also include Raman spectroscopy. Although IR and Raman spectroscopy are complementary techniques, widespread use of the Raman technique in pharmaceutical investigations has been limited. Before the advent of Fourier transform techniques and lasers, experimental difficulties limited the use of Raman spectroscopy. Over the last 20 years a renaissance of the Raman technique has been seen, however, due mainly to instrumentation development. [Pg.60]

XRPD as a stability-indicating assay method When the phase identity, or degree of crystallinity (or lack thereof), of a drug substance is important to its performance in a drug product, XRPD can serve as a vital stability-indicating assay method. There is no doubt that XRPD can be validated to the status of any other stability-indicating assay, and that one can use the usual criteria of method validation to establish the performance parameters of the method. This aspect would... [Pg.216]

Several in vitro tests are currently employed to assure drug product quality. These include purity, potency, assay, content uniformity, and dissolution specifications. For a pharmaceutical product to be consistently effective, it must meet all of its quality test criteria. When used as a QC test, the in vitro dissolution test provides information for marketing authorization. The dissolution test forms the basis for setting specifications (test, methodology, acceptance criteria) to allow batch release into the market place. Dissolution tests also provides a useful check on a number of physical characteristics, including particle size distribution, crystal form, etc., which may be influenced by the manufacturing procedure. In vitro dissolution tests and QC specifications should be based on the in vitro performance of the test batches used in in vivo studies or on suitable compendial specifications. For conventional-release products, a single-point dissolution... [Pg.82]

As described in the following chapter, there are many biopharmaceutical applications of protein assays. Assigning the protein concentration for the drug substance, drug product, or in-process sample is often the first task for subsequent analytical procedures because assays for purity, potency, or identity require that the protein concentration be known. Hence it is typical for several different methods to be employed under the umbrella of protein concentration measurement, depending on the requirements of speed, selectivity, or throughput. The protein concentration is valuable as a stand-alone measurement for QC and stability of a protein. However, protein concentration methods provide no valuable... [Pg.14]

Finally, the protein assay for the drug product will also be used for realtime and accelerated stability testing if it has been validated to be stability indicating. A stability-indicating protein concentration method usually translates to a method that can reveal how much protein can be recovered from the dosage form. Many protein instabilities result in precipitation of the protein and adsorption to the container. An instability that results in only a modification of the protein structure but not in loss of protein from solution will not be detected by a sequence-independent protein assay such as a colorimetric assay. [Pg.22]

In addition to its use in quantitating the product, ELISA can also be used as a readout tool for cell-based bioassays or other assays that measure a biological activity conferred by the drug product. The end point of the bioassay may be a... [Pg.282]

This chapter provides the novice and the experienced analyst with an overview of sample preparation techniques focusing on solid dosage forms. It describes the best practices in the dilute and shoot approach, and the tricks of the trade in grinding, mixing, sonication, dilution and filtration of drug products. Selected case studies of sample preparations for assays and impurity testing are used to illustrate the strategies, trade-offs... [Pg.123]


See other pages where Drug product assays is mentioned: [Pg.129]    [Pg.629]    [Pg.630]    [Pg.79]    [Pg.348]    [Pg.176]    [Pg.79]    [Pg.129]    [Pg.629]    [Pg.630]    [Pg.79]    [Pg.348]    [Pg.176]    [Pg.79]    [Pg.328]    [Pg.337]    [Pg.75]    [Pg.406]    [Pg.337]    [Pg.346]    [Pg.252]    [Pg.260]    [Pg.33]    [Pg.488]    [Pg.73]    [Pg.666]    [Pg.22]    [Pg.22]    [Pg.23]    [Pg.24]    [Pg.281]    [Pg.294]    [Pg.302]    [Pg.36]    [Pg.5]    [Pg.7]    [Pg.124]    [Pg.134]   
See also in sourсe #XX -- [ Pg.140 , Pg.141 ]




SEARCH



© 2024 chempedia.info